<DOC>
	<DOCNO>NCT00258739</DOCNO>
	<brief_summary>Primary objective : - To classify 2 study group , accord tumoral response . Secondary objective : - To evaluate percentage focus control per year . - To calculate time progression . - To evaluate safety profile .</brief_summary>
	<brief_title>Docetaxel Non Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Non small cell lung cancer confirm histology cytology . IIIB stage , except exist pleural discharge , upper cava vein syndrome supraclavicular affectation General stage 01 ECOG scale Loss weight le 5 % 3 previous month diagnose . Pulmonary function gasometry result : FEV1 &gt; 30 % 1 l , DLCO ( diffuse capacity lung carbon monoxide ) &gt; 30 % , PCO2 &lt; 45 mmHg PO2 &gt; 60 mmHg . Normal medullar function ( hemoglobin &gt; 11 g/dl , total WBC &gt; 1,5 x 10^9/l , platelet &gt; 100 x 10^9/l ) Appropriate renal hepatic function CTScan Anticonceptive method Available laboratory test ( maximum 1 month ) Exclusion criterion : Pleural discharge , upper cava vein syndrome supraclavicular affectation . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
</DOC>